Orion Pharma Limited (DSE:ORIONPHARM)
Bangladesh
· Delayed Price · Currency is BDT 28.60
+0.60 (2.14%)
At close: Dec 3, 2025
Orion Pharma Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Revenue | 3,230 | 4,082 | 10,621 | 13,927 | 9,662 | 10,833 | Upgrade
|
| Revenue Growth (YoY) | -62.69% | -61.57% | -23.74% | 44.14% | -10.81% | 41.64% | Upgrade
|
| Cost of Revenue | 1,968 | 2,706 | 8,348 | 11,652 | 7,693 | 8,198 | Upgrade
|
| Gross Profit | 1,262 | 1,376 | 2,273 | 2,275 | 1,969 | 2,635 | Upgrade
|
| Selling, General & Admin | 1,315 | 1,320 | 1,344 | 1,282 | 1,294 | 1,138 | Upgrade
|
| Other Operating Expenses | - | - | - | - | - | -41.7 | Upgrade
|
| Operating Expenses | 1,315 | 1,320 | 1,344 | 1,282 | 1,294 | 1,096 | Upgrade
|
| Operating Income | -53.71 | 55.9 | 929.02 | 992.96 | 675.12 | 1,538 | Upgrade
|
| Interest Expense | -453.09 | -431.89 | -393.38 | -148.29 | -173.23 | -223.43 | Upgrade
|
| Interest & Investment Income | 4.5 | 4.72 | 5.07 | 3.31 | 638.31 | 3.19 | Upgrade
|
| Earnings From Equity Investments | 7.75 | 7.62 | 9.21 | 9.13 | 9.3 | 6.07 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.69 | 0.69 | 0.71 | 0.89 | 0.62 | 1.23 | Upgrade
|
| Other Non Operating Income (Expenses) | -22.68 | -15.68 | -14.75 | -16.91 | -86.74 | -131.51 | Upgrade
|
| EBT Excluding Unusual Items | -516.53 | -378.64 | 535.89 | 841.09 | 1,063 | 1,194 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0 | -0 | -2.86 | 0.21 | 0.08 | -5.93 | Upgrade
|
| Pretax Income | -516.53 | -378.64 | 533.03 | 841.3 | 1,063 | 1,193 | Upgrade
|
| Income Tax Expense | 104.49 | 107.65 | 181.26 | 147.07 | 172.71 | 68.51 | Upgrade
|
| Earnings From Continuing Operations | -621.02 | -486.3 | 351.77 | 694.23 | 890.75 | 1,125 | Upgrade
|
| Minority Interest in Earnings | 80.63 | 71.02 | -33.65 | -53.29 | -44.67 | -185.68 | Upgrade
|
| Net Income | -540.39 | -415.28 | 318.12 | 640.94 | 846.08 | 939.06 | Upgrade
|
| Net Income to Common | -540.39 | -415.28 | 318.12 | 640.94 | 846.08 | 939.06 | Upgrade
|
| Net Income Growth | - | - | -50.37% | -24.25% | -9.90% | 41.07% | Upgrade
|
| Shares Outstanding (Basic) | 234 | 234 | 234 | 234 | 234 | 234 | Upgrade
|
| Shares Outstanding (Diluted) | 234 | 234 | 234 | 234 | 234 | 234 | Upgrade
|
| EPS (Basic) | -2.31 | -1.77 | 1.36 | 2.74 | 3.62 | 4.01 | Upgrade
|
| EPS (Diluted) | -2.31 | -1.77 | 1.36 | 2.74 | 3.62 | 4.01 | Upgrade
|
| EPS Growth | - | - | -50.37% | -24.25% | -9.90% | 41.07% | Upgrade
|
| Free Cash Flow | 784.49 | 336.97 | -361.87 | -1,366 | -1,505 | -1,685 | Upgrade
|
| Free Cash Flow Per Share | 3.35 | 1.44 | -1.55 | -5.84 | -6.43 | -7.20 | Upgrade
|
| Dividend Per Share | - | - | 1.000 | 1.000 | 1.000 | 1.200 | Upgrade
|
| Dividend Growth | - | - | - | - | -16.67% | 20.00% | Upgrade
|
| Gross Margin | 39.06% | 33.71% | 21.40% | 16.33% | 20.38% | 24.32% | Upgrade
|
| Operating Margin | -1.66% | 1.37% | 8.75% | 7.13% | 6.99% | 14.20% | Upgrade
|
| Profit Margin | -16.73% | -10.17% | 3.00% | 4.60% | 8.76% | 8.67% | Upgrade
|
| Free Cash Flow Margin | 24.29% | 8.25% | -3.41% | -9.81% | -15.58% | -15.56% | Upgrade
|
| EBITDA | 490.94 | 673.35 | 1,500 | 1,574 | 1,148 | 2,529 | Upgrade
|
| EBITDA Margin | 15.20% | 16.50% | 14.12% | 11.30% | 11.88% | 23.34% | Upgrade
|
| D&A For EBITDA | 544.65 | 617.45 | 570.84 | 580.89 | 472.83 | 990.2 | Upgrade
|
| EBIT | -53.71 | 55.9 | 929.02 | 992.96 | 675.12 | 1,538 | Upgrade
|
| EBIT Margin | -1.66% | 1.37% | 8.75% | 7.13% | 6.99% | 14.20% | Upgrade
|
| Effective Tax Rate | - | - | 34.01% | 17.48% | 16.24% | 5.74% | Upgrade
|
| Advertising Expenses | - | 19.47 | 26.24 | 20.53 | 19.65 | 21.74 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.